An interventional study of KOPPsupport and Moodpep in Mood Disorders, Mood Disorders in Children and Adolescents and Depressive Symptoms, sponsored by Erasmus Medical Center. Recruiting at 5 sites in Netherlands. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Bipolar Disorder with a site in Netherlands — 6 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Netherlands.
Among the 15 studies in Bipolar Disorder with a site in Netherlands, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 with no phase, and was the 15th registered.
1,684 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
Browse Bipolar Disorder studies →6 of the 15 studies in Bipolar Disorder with a site in Netherlands are open now. Recruiting first, the newest first:
Geestelijke Gezondheidszorg Eindhoven (GGzE) · Sites in Netherlands
Ages 16–35
Leiden University Medical Center · Sites in Netherlands
Ages 18+
Universiteit Leiden · Sites in Netherlands
Ages 18–65
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Ludwig-Maximilians - University of Munich · Sites in Netherlands, Austria, Germany
Ages 18–65
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 205 Bipolar Disorder studies recruiting now, 59 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 37 take children under 18; 50 take healthy volunteers.
This study: 10 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 154 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Median enrollment 142 across the 12 interventional studies, 80 across the 3 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 183 are open to participants now.
Erasmus Medical Center has 1 study filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
3 of the studies in Bipolar Disorder with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06134349Leiden University Medical CenterThe Bipolar Lithium Imaging Scan Study. | 2027-03-01 |
| NCT07938593Erasmus Medical CenterPreventing Mood Disorders in High-risk Offspring: Protocol for the Randomized Controlled Trial of the MARIO Online Preventive Intervention Platform | 2027-04-01 |
| NCT06282250Geestelijke Gezondheidszorg Eindhoven (GGzE)Seeing the Light: Early Intervention in People at Risk for Bipolar Disorder | 2027-11-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Bipolar Disorder with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Children of parents with a mental illness (COPMI) have an increased likelihood of developing mood disorders such as major depressive disorder or bipolar disorder. Especially adolescence is a particularly vulnerable time for the development of mood disorders. It is therefore important to intervene early to prevent the development of mood disorder symptoms and fully established mood disorders. This proposed MARIO online preventive intervention trial aims to examine the potential effects of access to an online platform (the MARIO preventive intervention platform), that integrates three preventive online interventions, on the development of mood disorder symptoms in COPMI. With a target sample size of N = 154 offspring - aged between 10 to 25 years - of parents with a mental illness, the researchers will conduct one of the largest Randomized Controlled Trials (RCT) for online preventive interventions in a high-risk offspring population to date. Participants in the experimental condition will receive 3 months access to the MARIO online preventive intervention platform through which participants can take part in up to 3 online preventive interventions for mood disorders. These intervention components include content targeted at COPMI specifically, including psychoeducation, social support, the implementation of adaptive coping strategies, and improving affective awareness. The preventive interventions will take between 4 and 8 weeks to complete. Outcome assessments take place in all participants at baseline (T0) and post-intervention (T1), as well as at 3-month (T2) and 9-month (T3) follow-up. Some outcomes are assessed at all time points, while others are only assessed at baseline (T0) and 9-month follow-up (T3).
The primary outcome measure are depression symptoms, assessed with the Patient Health Questionnaire (PHQ-9) at post-intervention and at 3-month follow-up. Secondary outcomes include depressive symptoms at 9-month follow-up as well as bipolar mood disorder symptoms, psychosocial functioning, and usage of adaptive coping strategies across all time points. These secondary outcomes are also assessed using self-report questionnaires. The potential onset of a mood disorder is assessed as a secondary outcome using a clinical interview at 9-month follow-up. This interview is only conducted with participants who show significant mood disorder symptoms at any of the 4 time points, indicated by a PHQ-9 score of 5 and above.
With this RCT design, the researchers can assess if access to a platform with three online preventive interventions can help in preventing mood disorder symptoms in COPMI. This can deepen the understanding of vulnerabilities and needs for this high-risk population, which will hopefully contribute to improved long-term mental health outcomes.
1,684 studies on the registry are indexed under Bipolar Disorder; 267 are open to participants now.
This study's planned enrollment of 154 is above the median of 64 across 1,279 interventional studies indexed under Bipolar Disorder.
Browse Bipolar Disorder studies →Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 183 are open to participants now.
Compared within Bipolar Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Mood Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Current depressive or bipolar disorder diagnosis and/or suicidality based on the K-SADS psychiatric interview that is conducted at baseline. In case of a mild current depressive episode during the interview, the researchers will ask participants about agreeing to another K-SADS psychiatric interview (on mood symptoms and suicidality) after a period of 6 months. If participants agree, and there is no current mood episode after the 6 months waiting period according to the K-SADS psychiatric interview, participants are eligible to participate in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this study, the researchers will be investigating the MARIO preventive intervention platform. This platform offers up to three types of preventive intervention components. The first preventive intervention component is KOPPsupport, an existing psycho-educational program for COPMI in the age of 16-25 years. The duration of the intervention is \~8 weeks. The second preventive intervention component is Moodpep, an intervention with cognitive behavioural therapy elements for individuals aged 18 years and older. It consists of 7 weekly modules which will take between 6-10 weeks to complete. The third preventive intervention component is the Grow It! app. It is an interactive tool, developed for youth in the age of 10 to 25 years. The app consists of three major components: 1. Increasing affective awareness through ESM surveys 2. Improving emotional reflection through individualized mood profiles 3. Strengthening adaptive coping strategies through CBT-based challenges
Behavioral: KOPPsupport · Behavioral: Moodpep · Behavioral: Grow It!
Participants who are assigned to the control condition do not receive access to the MARIO preventive intervention platform. During the 12 months of the study, participants get regular care if needed via the health care system in place. After 12 months, the researchers inform participants about the three online interventions, so that participants can use them independently from the MARIO study, in case these participants want to do so and are eligible for participation in the preventive intervention.
KOPPsupport is an existing psycho-educational program for COPMI, developed by the Trimbos institute for participants aged 16 to 25 years (Woolderink et al., 2010). It is designed to strengthen protective factors to prevent mental health issues. Registration occurs via the MARIO platform, after which participants are redirected to the KOPPsupport website (https://www.koppsupport.nl/) where they can sign up for a specific starting date. Depending on group start dates, participants may wait for up to 4 weeks before starting the intervention. The intervention itself consists of eight weekly online chat group meetings, guided by mental health professionals. The sessions cover topics including thoughts and feelings, questions about addictions and mental problems, roles in the family, and different styles of behavior. Before each session, participants are also required to carry out homework assignments about the topic that will subsequently be discussed in that session.
Moodpep is an online preventive intervention with CBT-based elements (VUmc; Garnefski \& Kraaij, 2023). While Moodpep is developed for individuals aged 18 years and older, participants younger than 18 can still select it on the MARIO intervention platform. It consists of 7 different modules in a fixed order that participants are instructed to complete within 8 weeks. The CBT-based modules aim to encourage new activities, improve relaxation, reduce negative thoughts, and assist in working towards personal goals. Tasks within the modules include the completion of a daily diary, different psychoeducational exercises, and suggestions for COPMI to develop ideas about reaching personal goals. Users are also in regular online contact with a trained coach who is a member of the MARIO research team. The coach gives asynchronous feedback within 3 working days about the participants' completed modules, is available to talk about potential problems, and encourages continued participation.
Grow It! is a gamified smartphone app for youth between the ages of 10 and 25 years. The app consists of three major components: 1) Increasing affective awareness via ESM surveys; 2) improving emotional reflection via a personalized visual mood profile; and 3) improving adaptive coping through daily CBT-based challenges. To improve app interactivity, fun, and user friendliness, the app includes the choice for an avatar and other ways to personalize the app. Participants use the Grow It! app for four weeks. There must be at least 4 people available to build a team for the intervention to start. If less than 4 people sign up over the course of these four weeks, the remaining spots are filled by members of the research team who are instructed to also use Grow It! regularly during the intervention period.
Development of depressive symptoms post-intervention and at 3-month follow-up
Depressive symptoms post-intervention and at 3-month follow-up are measured with the Patient Health Questionnaire 9 (PHQ-9; Kroenke et al, 2001). Participants indicate how often they experienced symptoms (e.g., "How often in the past two weeks did you have little interest or pleasure in things that you do?") on a 4-point scale (0 = not at all, 1 = on some days, 2 = more than half of the days, 3 = (almost) every day). The original nine items were extended to ten items, by rephrasing some of the items and splitting item 8 ("How often in the past two weeks were you moving or speaking so slowly that other people could have noticed, or the opposite - were you so fidgety or restless that you have been moving around a lot more than usual?") into two questions (Items 8a and 8b). A higher total score across all items indicated higher depressive symptoms. However, scores on items 8a and 8b were converted into a singular score by selecting the item that was scored higher by each participant.
Time frame: Measurement at baseline (Month 0), post-intervention (T1; Month 3), and 3-month follow-up (T2; Month 6).
Depressive symptoms at 9-month follow-up
Depressive symptoms at 9-month follow-up are measured with the PHQ-9 as well. Participants indicate how often they experienced depressive symptoms (e.g., "How often in the past two weeks did you have little interest or pleasure in things that you do?") on a 4-point scale (0 = not at all, 1 = on some days, 2 = more than half of the days, 3 = (almost) every day). The original nine items were extended to ten items, by rephrasing some of the items and splitting item 8 ("How often in the past two weeks were you moving or speaking so slowly that other people could have noticed, or the opposite - were you so fidgety or restless that you have been moving around a lot more than usual?") into two separate questions (Items 8a and 8b). A higher total score across all items indicated higher depressive symptoms. However, scores on items 8a and 8b were converted into a singular score by selecting the item that was scored higher by each participant.
Time frame: At 9-month follow-up (T3; Month 12)
Bipolar mood disorder symptoms
Bipolar mood disorder symptoms are measured with the MARIO-check at all time-points, consisting of depression items from the PHQ-9 and mania items from the K-SADS COMP (Townsend et al., 2020) and GBI (Depue et al, 1981). The mania items capture decreased need for sleep, racing thoughts, and increases in energy and goal-directed activity. One item assesses psychotic-like symptoms. Participants indicate how often they experienced these symptoms on a 4-point scale (0 = not at all, 1 = on some days, 2 = more than half of the days, 3 = (almost) every day). A higher score across all 4 items indicates higher bipolar mood disorder symptoms.
Time frame: At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).
Adaptive coping
The usage of adaptive coping strategies is measured at all time points by items from the Utrecht Coping List Adolescent version (Bijstra et al., 1994). The scale consists of 47 items. 21 items measure adaptive coping strategies (e.g., "When I have a problem, I try to think of concrete ways to solve it."), while 26 items measure maladaptive coping strategies (e.g., "I feel overwhelmed and don't know what to do."). Items are scored on a scale from 1 (never) to 4 (very often), with total scores of the subscales indicating higher adaptive coping (scores from 21 to 84) and maladaptive coping (scores from 26 to 104), respectively.
Time frame: At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).
Psychosocial functioning
Psychosocial functioning is assessed at all time points with 10 items from the PROMIS pediatric Fatigue item bank (Lai et al., 2013). Participants rate items (e.g., "I had enough energy to do my usual things at home") on a scale from 0 (never) to 4 (almost always), with higher total scores of all items (0 to 40) indicating higher psychosocial functioning.
Time frame: At baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; Month 6), and 9-month follow-up (T3; Month 12).
The likelihood of onset of a mood disorder at 9-month follow-up
Onset of depression or bipolar disorder is measured using the depression and mania sections of the computerized version of the K-SADS diagnostic interview (Kaufman et al., 1997). These sections include questions about a variety of current (in the past two weeks; at T3 over the past 12 months) and lifetime depression and mania symptoms. The sections also assess potential current and past suicidality and self-harm in participants. The interview is conducted for all participants as part of the screening procedure at T0, and at T3 for all participants who received a PHQ-9 score ≥ 5 (indicating mild depressive symptoms) in the MARIO-check at any of the time points. Interviews are conducted on the phone by a member of the research team and take approximately 20 to 30 minutes to complete.
Time frame: PHQ-9 at baseline (Month 0), post-intervention (T1; Month 3), 3-month follow-up (T2; M), and 9-month follow-up (T3; Month 12). If participants report a PHQ-9 score of 5 or above at any time point a K-SADS diagnostic interview is conducted at Month 12.
Plan to share: Undecided — Individual participant data can be shared upon request to the principal investigators at mario@amsterdamumc.nl. Researchers who are interested in the data need to submit a detailed statistical analysis plan, outlining which variables are of interest to answer specific research questions and to test specific hypotheses. Both internal and external researchers can only receive data if the Principal Investigators have approved this analysis plan. Privacy-sensitive data will not be shared outside the MARIO data management team. Primary and secondary outcome data will not be shared with researchers (internal or external) before conclusion of data collection on April 1st, 2027.
Started Nov 2022 (actual). Primary completion is estimated for Apr 2027, 52 months after the start.
Of 354 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 52 months is above that.
Counting every sponsor, half of 356 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.